Neogen (NEOG) Stock Jumps 11% on Raised FY2027 Outlook

undefined

Neogen (NEOG) shares rose about 11% after the food-safety company raised fiscal 2027 revenue guidance to $885-890 million on a stronger-than-expected quarter.

Lead

The quarter ended August 31 produced revenue of $222.8 million, up from $209.2 million a year earlier. Adjusted earnings were $0.08 per share, $0.03 above the consensus estimate of $0.05. Revenue topped the consensus figure of roughly $208.2 million.

What Did Neogen Report for the Quarter?

Neogen reported 6.5% revenue growth and 8.1% core growth, which strips out the effect of divestitures and currency. Adjusted EBITDA reached $41.6 million, an 18.7% margin that was 170 basis points wider than a year earlier.

On a GAAP basis the company posted a net loss of $11.9 million, or $0.05 per share. The year-earlier quarter showed net income of $36.3 million, which included a $76.4 million gain from a divestiture. Adjusted net income was $17.5 million, compared with $9.5 million in the prior-year period.

Operating cash flow was $12.9 million and free cash flow was $4.7 million, an improvement of about $18 million from the year-earlier quarter. Neogen ended the period with $172.0 million in cash and $774.2 million in non-current debt.

How Did the Two Segments Perform?

Both segments grew, with Food Safety contributing the bulk of the gain. Food Safety revenue rose 7.4% to $163.2 million, about 73% of the total, with core growth of 8.1%. Indicator testing and culture media products grew about 11%.

Chief Executive Mike Nassif described the quarter as an acceleration from the prior period, tied to improved commercial execution and product strength.

Why Did the Stock React This Way?

The shares rose sharply because the quarter beat on revenue and earnings and because management raised guidance after an extended period of operational difficulty. The stock had traded at a discount to its own history, at roughly three times sales against a long-run median above seven times.

Margin expansion and cash generation also mattered. The company carries sizable debt, so the improvement in free cash flow and the widening EBITDA margin addressed a central concern about its balance sheet. The guidance increase was modest in dollar terms, but it signaled that the first-quarter strength was not expected to reverse.

What Is the Petrifilm Transition and Why Does It Matter?

The Petrifilm transition is a multi-quarter move of manufacturing for the company's culture-media testing plates. It is the largest operational risk in the outlook. The first product unit was fully validated in August, which management called a major de-risking milestone. Saleable product is on track to be manufactured and the broader transition begins in November 2026, covering 17 product variants.

Management expects the project to add 200-300 basis points of margin by fiscal 2029. Production transfers of this kind can disrupt supply and add cost during the changeover, so execution over the coming quarters will shape whether the raised guidance holds.

Strategic Context

Neogen has been reshaping its portfolio and cost base. A pending divestiture of its genomics business is expected to bring in about $140 million in proceeds. The company has already recorded one divestiture gain, in the year-earlier quarter. Proceeds from the pending sale could be used to reduce the $774.2 million debt load, though the company has not tied them to a specific use in its results release.

Outlook

Neogen enters the second quarter with guidance that implies continued growth in the mid-to-high single digits, a margin trajectory that is improving, and a manufacturing transition that begins next month. The guidance increase is small, but it follows a revenue beat of roughly 7% against consensus. The Petrifilm transfer, the genomics sale and the pace of debt reduction are the next measurable tests for the company.